Volume 4.16 | Apr 26

Mammary Cell News 4.16 April 26, 2012
Mammary Cell News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter

Scientists Re-Write Rulebook on Breast Cancer in Landmark Global Study
Researchers have reclassified breast cancer into 10 completely new categories based on the genetic fingerprint of a tumor. [Press release from BC Cancer Agency discussing online prepublication in Nature] Press Release | Abstract

Description Apply Now: Mammary Stem Cell Training Course (June 2-3 2012) in Vancouver, Canada.

PUBLICATIONS (Ranked by Impact Factor of the Journal)


Quantitative Proteomics Profiling of Murine Mammary Gland Cells Unravels Impact of Annexin-1 on DNA-Damage Response, Cell Adhesion and Migration
To elucidate how annexin 1 (ANXA1) plays a role in breast cancer initiation, scientists performed stable isotope labeling of amino acids in cell culture analysis on normal mammary gland epithelial cells from ANXA1-heterozygous and ANXA1-null mice. [Mol Cell Proteomics] Abstract

Induction of the RNA Regulator LIN28A Is Required for the Growth and Pathogenesis of RESTless Breast Tumors
Researchers demonstrated that loss of REST results in up-regulation of LIN28A, a known promoter of tumor development, in breast cancer cell lines and human breast tumors. [Cancer Res] Abstract

Elf5 Regulates Mammary Gland Stem/Progenitor Cell Fate by Influencing Notch Signaling
Scientists demonstrated that, in addition to regulating terminal differentiation of alveolar cells, Elf5 also plays a critical role in determining cell fate and in regulating the stem/progenitor function of the mammary epithelium. [Stem Cells] Abstract

A Mouse Model with T58A Mutations in Myc Reduces the Dependence on KRas Mutations and Has Similarities to Claudin-Low Human Breast Cancer
To examine Myc dependence upon Ras mutations, researchers generated MMTV regulated Myc and Myc T58A transgenic mice. [Oncogene] Abstract

The Ras-Like Protein R-Ras2/TC21 Is Important for Proper Mammary Gland Development
Investigators used RRas2 knockout mice expressing β-galactosidase under the regulation of the endogenous RRas2 promoter to investigate the function of R-Ras2/TC21 in vivo. [Mol Biol Cell] Abstract

Deficiency of the p53/p63 Target Perp Alters Mammary Gland Homeostasis and Promotes Cancer
Given that p63 is essential for proper mammary gland development and that cell adhesion is fundamental for ensuring the proper architecture and function of the mammary epithelium, scientists investigated Perp’s function in the mammary gland. [Breast Cancer Res] Abstract | Press Release

Specific β-Containing Integrins Exert Differential Control on Proliferation and 2D Collective Cell Migration in Mammary Epithelial Cells
Researchers describe the consequences of removing the β1-integrin gene from primary cultures of mammary epithelial cells in situ using CreER. [J Biol Chem] Abstract

Thermal Targeting of an Acid-Sensitive Doxorubicin Conjugate of Elastin-Like Polypeptide Enhances the Therapeutic Efficacy Compared to the Parent Compound In Vivo
Investigators evaluated the therapeutic potential of elastin-like polypeptides in delivering doxorubicin in the E0771 syngeneic mouse breast cancer model. [Mol Cancer Ther] Abstract

Basal-Like Breast Cancer Cells Induce Phenotypic and Genomic Changes in Macrophages
This study investigated monocyte-to-macrophage differentiation and polarization, and gene expression in response to co-culture with basal-like versus luminal breast cancer cells. [Mol Cell] Abstract


Metronomic Chemotherapy Combined with Bevacizumab and Erlotinib in Patients with Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
The object of this study was to evaluate the safety and efficacy of metronomic chemotherapy in combination with bevacizumab and erlotinib in patients with HER2-negative metastatic breast cancer and poor hormone receptor expression. [Clin Breast Cancer] Abstract

First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
The authors conducted an exploratory analysis of patients with triple-negative breast cancer treated in the single-arm routine oncology practice ATHENA study. [Oncology] Abstract

50,000 scientists receive our newsletters. Do your colleagues? Click to share this newsletter now.


Researchers Find Potential Link Between Drinking Alcohol and Breast Cancer
Alcohol consumption has long been established as a risk factor for breast cancer. But finding the direct link that makes it so has so far proved elusive. Now, investigators think that they have found the answer, a protein called CYP2E1. [Press release from Experimental Biology discussing research presented at the Experimental Biology 2012 Conference, San Diego] Press Release

New Research Shows Link Between Common Environmental Contaminant and Rapid Breast Cancer Cell Growth
Studies show that breast cancer cells become increasingly aggressive the longer they are exposed to small concentrations of cadmium, a heavy metal commonly found in cosmetics, food, water and air particles. [Press release from Experimental Biology discussing research presented at the Experimental Biology 2012 Conference, San Diego]
Press Release

Study: Different Survival Rates Have Been Found for Node-Negative Breast Cancer Patients with the Same Tumor Size When Patients Are Placed into Risk Groups that Vary by Age, Race and Hormone Receptor Status
Research indicates that tumor size stratified by age, race and hormone receptor status helps predict survival in node-negative breast cancer patients. [Press release from The Cancer Institute of New Jersey discussing research presented at the Society of Surgical Oncology’s 65th Annual Cancer Symposium, Orlando]
Press Release


McKee Medical Center Foundation receives $75,000 Grant from Komen
The McKee Medical Center Foundation has accepted a grant for $75,000 from the Denver Metropolitan Affiliate of Susan G. Komen for the Cure® to provide money for breast cancer treatment for uninsured and under-insured women across Northern and Northeastern Colorado. [Banner Health] Press Release

Galena Biopharma Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $14.5 Million Public Offering of Common Stock
Galena Biopharma announced that it has closed the previously announced underwritten public offering of 9,751,500 shares of its common stock at a price to the public of $1.50 per share for gross proceeds of approximately $14.5 million. The company intends to use the net proceeds of the offering for working capital and other general corporate purposes, including the Phase III NeuVax™ PRESENT clinical trial and a planned Phase II trial of NeuVax in combination with Herceptin®. [Galena Biopharma] Press Release

German Federal Regulator Confirms Additional Benefit of Anticancer Agent Halaven® for Metastatic or Locally Advanced Breast Cancer
Eisai Co., Ltd. announced that the German Federal Joint Committee (G-BA) considers the use of Halaven® to have additional benefit versus comparative treatments, defined by the G-BA for women who have already had extensive prior treatment for metastatic or locally advanced breast cancer. [Eisai Co., Ltd.]
Press Release

Eisai Announces Canadian Launch of Halaven® (Eribulin Mesylate) Injection for the Treatment of Metastatic Breast Cancer
Eisai Limited announced the launch of Halaven® (eribulin mesylate), the latest treatment approved by Health Canada for metastatic breast cancer. [PR Newswire] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Centre for Regenerative Medicine: Driving Stem Cell Research Towards Therapy
May 21-22, 2012
Edinburgh, United Kingdom

NEW Gordon Research Conference: Mammary Gland Biology
June 9-10, 2012
Lucca, Italy

Visit our events page to see a complete list of events in the mammary cell community.


Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – hPSC (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Position – Breast Cancer/Stem Cell Biology (University of Cincinnati – College of Medicine)

Postdoctoral Position – Translational Breast Cancer Research (ISREC/EPFL)

Postdoctoral Position – Breast Cancer Biology (Bellvitge Institute for Biomedical Research)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Middle East to Asia Pacific

E-mail [email protected] to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us